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Article highlights 
 
• Effectiveness of current pharmacological treatments is limited with many 
patients discontinuing use. 
 
• Several drugs with diverse mechanisms of action are being investigated as 
potential treatment approaches. 
 
• The current and potential drugs primarily focus on suppression of central 
neuronal hyper-excitability. 
 
• Modest efficacy has been reported for a few drugs against selective 
symptoms such as pain, anxiety and depression. 
 
• Although primary focus has been towards modulation of bioamines and of the 
α2δ subunits of neuronal calcium channels, drugs acting on novel targets 
such as cannabinoid receptors, melatonin receptors and potassium channels 
are being investigated. 
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Abstract 
Introduction: Fibromyalgia (FM) is a common, complex chronic widespread pain 
condition is characterized by fatigue, sleep disturbance and cognitive dysfunction. 
Treatment of FM is difficult, requiring both pharmacological and non-pharmacological 
approaches, with an empiric approach to drug therapy focused toward individual 
symptoms, particularly pain. The effectiveness of current medications is limited with 
many patients discontinuing use. 
Areas Covered: A systemic database search has identified 26 molecular entities as 
potential emerging drug therapies. Advances in the understanding of the 
pathophysiology of FM provides clues to targets for new medications. Investigation 
of bioamine modulation and α2δ ligands and novel targets such as dopamine 
receptors, NMDA receptors, cannabinoid receptors, melatonin receptors and 
potassium channels has identified potential drug therapies.  
Expert opinion: Modest improvement of health status in patients with FM has been 
observed with drugs targeting a diverse range of molecular mechanisms. No single 
drug, however, offered substantial efficacy against all the symptoms characteristic of 
FM. Identification of new and improved therapies for FM needs to address the 
heterogeneity of the condition, which suggests existence of patient subgroups, the 
relationship of central and peripheral aspects of the pathophysiology and a 
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requirement of combination therapy with drugs targeting multiple molecular 
mechanisms.  
   
 
Keywords: fibromyalgia, clinical trials, central sensitization, pain, fatigue, cognitive 
dysfunction.  
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1. Introduction 
Fibromyalgia (FM) is characterised by the core symptoms of generalized chronic 
pain, fatigue, stiffness, and sleep disturbance of variable intensity and thus 
considered to be a phenotype of a large spectrum of disorders that have substantial 
overlap [1-5]. In addition, the cognitive performance (working memory, verbal fluency, 
episodic memory) of FM patients is poor with the distraction of chronic pain and 
fatigue contributes to increased impairment of cognition [6,7]. The condition affects 
2-4% of populations worldwide, is 7 times more prevalent in females than males and 
is complicated by the occurrence of co-morbidities which often belong to the family of 
CSS exhibiting similar symptoms [1-5].  
Although aspects of the pathophysiology of FM are still unclear, evidence of 
involvement of genetics, neurotransmitter and neuroendocrine dysfunctions, 
autonomic nervous system (ANS) dysfunction, and psychophysiological and cerebral 
abnormalities has been demonstrated [1-6]. Biological amplification of sensory 
stimuli (eg mechanical and electrical stimulation, heat, auditory tones) as a result of 
decreased thresholds are consistent with the pathophysiology of FM [9]. The most 
common symptom is chronic widespread pain with hyperalgesia (an increased 
response to a stimulus expected to cause pain) and allodynia (pain caused by a non-
noxious stimulus). The presence of central sensitization (CS), an amplified response 
of the central nervous system to peripheral input, is a characteristic of central 
sensitivity syndromes where neuronal excitability and hypersensitivity leads, at least, 
to persistent pain [1-4]. The pain in FM being associated with CS is consistent with 
an aberrant mechanism of the central nervous system (CNS) processing that causes 
hypersensitivity to peripheral input. In addition to the central aspects of the condition, 
the role of peripheral nociceptive generators enhancing the level of CS and the 
extent of symptoms characteristic of the FM has increasingly received attention. An 
interrelationship of the various components that could contribute to the 
pathophysiology of FM acting as amplifiers of each other has been suggested as a 
cyclic model [5]. Peripheral nerve pathologies, neuroinflammation and skeletal 
muscle abnormalities and ischaemia have been reported to contribute to the 
pathophysiology of FM [4,10]. Peripheral small nerve fibre function impairment and 
epidermal nerve fibre density reduction that may be associated with small fibre 
neuropathy has been observed in patients with FM [11]. Evidence from a number of 
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studies support the role of small fibre neuropathy in a subset of FM patients [4,12].  
Structural, functional and metabolic alterations in skeletal muscle reported in FM 
patients include decreased respiratory enzyme activity, distribution of mitochondria, 
oxidative stress, production of pro-inflammatory cytokines [3,4]. The results have 
been inconsistent. In addition, a cause of muscle pain in FM patients being 
associated with aspects of ischaemia such as oxygen uptake and metabolism, 
lactate accumulation and blood flow have been the subject of investigation [3,4]. 
Although data are inconclusive, enlarged arteriole-venule shunts due to an increase 
peptidergic and sympathetic innervation have been reported in FM patients which 
may contribute to muscle ischaemia and the pain and fatigue characteristic of FM 
[13]. Peripheral mechanisms involvement in the pathophysiology of FM needs to be 
taken into consideration in the management of the condition, because of the 
potential role of input generators to the predominant central mechanisms. Further 
work is awaited that will clarify the contribution (e.g. a cause or consequence of the 
condition, identify patient subsets) of the peripheral generators to the pathology of 
FM and thereby the potential as a treatment target.    
 
1.1 Neurotransmitters and central sensitization 
Altered neurotransmitter functionality (eg changed levels, sensitivity of receptors) are 
associated with the neurophysiological aspects of CS leading to enhanced 
excitability and increased spontaneous activity. The neurotransmitter abnormalities 
are associated with a progressive increase in response reflective of slow temporal 
summation (wind-up phenomena) leading to neuroplasticity perpetuating self-
sustaining CS without the need for further stimuli [1-4]. In the cerebrospinal fluid 
(CSF) of FM patients increased concentrations of substance P (2-3 fold), 
endogenous opioids (3-4 fold) and glutamate (2 fold) relative to healthy subjects 
have been observed [9]. In contrast, the CFS of FM patients have lower levels of 5-
HIAA, the main metabolite of serotonin, and 3-methoxy-4-hydroxyphenethylene 
(MPHG), the main metabolite of noradrenaline and blood levels of L-tryptophan and 
serotonin are lower compared to healthy controls [9]. Further, raised CSF levels of 
nerve growth factor and brain-derived neurotrophic factor have also been found in 
FM patients, which may be mediated through glutamatergic transmission [14,15]. 
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Harris et al [16] demonstrated that glutamate levels are higher in the posterior insula 
in FM patients than controls and these levels change in response to improvements in 
clinical pain and tenderness. The raised glutamate may be responsible for 
stimulation of N-methyl-D-aspartic acid (NMDA) glutamate receptors in the dorsal 
horn of the spinal cord responsible for the wind-up phenomenon [17]. In addition, the 
diffuse noxious inhibitory control (DNIC), which involves descending opioidergic and 
serotonergic-noradrenergic efferent pathways from the brain to the spinal cord that 
downregulate the pain signal, is aberrant in FM patients [18].   
Dopamine deficiency in the CNS has also been implicated in the pathophysiology of 
FM [19]. Dopamine is involved in regulation of CNS pain processing and chronic 
stress, which is implicated in FM, disrupts dopaminergic activity [20]. In patients with 
FM dopamine release into the basal ganglia in response to painful stimuli is 
attenuated or absent [19]. 
The cerebral mechanisms and abnormalities involved in CS identified in FM patients 
are reflected by increased activity in the pain processing regions of the brain during 
painful stimulation [1-4]. Functional imaging of the CNS has demonstrated an altered 
functioning within the somatosensory cortex, anterior and posterior cingulate, 
amygdala, medial frontal and parahippocampal gyrus and cerebellum in FM patients 
[21]. Interestingly, treatment with the tricyclic antidepressant amitriptyline, and 
thereby modulation of serotonin and noradrenaline levels, correlated clinical 
response with normalization of function within the bilateral thalamus and basal 
ganglia [22]. 
Familial predisposition and genetic polymorphisms have been identified with 
candidate genes associated with FM including the serotonin 5-HT2A receptor 
polymorphism T/T phenotype, serotonin transporter, dopamine 4 receptor and 
COMT (catechol O-methyltransferase) polymorphisms [23]. These polymorphisms 
affect metabolism or transport of monoamines and as identified play a role in 
sensory pain processing and human stress response. Insight into characterization of 
FM and possible classification of subgroups leading to more focused treatment with 
fewer adverse effects could be provided by improved understanding of the genetics 
of FM.  
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1.2 Stress processes 
FM patients have abnormal responses to stress and an inadequate reaction to 
stressful events which appear related to functional alterations of the ANS 
(dysautonomia) and neuroendocrine abnormalities of the hypothalamic-pituitary-
adrenal (HPA) axis [24]. The HPA axis in FM shows a decreased cortisol response, 
and increased adrenocorticosteriod hormone (ACTH) activity to a corticotrophin-
releasing factor challenge [17]. A decreased expression of corticosteroid receptors 
has been associated with the deviation of the HPA system in FM [25]. In addition, 
disrupted sleep architecture and a decrease in stage 4 sleep in FM patients may be 
related to decreased levels of growth hormone [26].  
Abnormalities of the ANS also seen in patients may be responsible for many of the 
additional symptoms reported in FM such as alterations in the cardiovascular system 
efficiency (through increased hypotension, variations in heart rate, pseudoRaynauds 
and microcirculatory vasoconstriction), sleep disturbance, dry eyes, and 
gastrointestinal and bladder disorders [27].  
 
1.3 Inflammation 
FM is not characterised by demonstrable tissue damage or inflammation, however 
the impact of the symptoms related to the pathophysiology, particularly CS, will lead 
to inactivity, exercise intolerance, skeletal muscle deconditioning and raised BMI. As 
a consequence, inflammatory mediators have been observed to be altered in 
patients with FM [28]. Various neurochemicals, such as substance P, that are raised 
in FM due to CS, stimulate a number of immune cells and increase the release and 
expression of inflammatory mediators (eg cytokines) at nerve endings, increasing 
nociceptive and sensory sensitivity [29]. Neurotransmitters, cytokines or chemokines 
can also activate glial cells and mast cells which can thus contribute to enhancement 
of the CNS activity and CS [1-4]. 
 
2. Pharmacological Management 
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Treatment of FM is challenging requiring both pharmacological and non-
pharmacological approaches often with an empiric approach to drug therapy focused 
toward individual symptoms with an emphasis to pain [3,5]. The efficacy of 
antidepressants (tricyclic, serotonin and noradrenaline reuptake inhibitors (SNRI) 
and selective serotonin reuptake inhibitors (SSRI)) in the reduction of pain, 
depression and fatigue, and improvement of quality of life has led to regular use in 
the treatment of FM patients [30]. The α2δ ligands, gabapentin and pregabalin, are 
also used regularly to manage the pain, sleep and fatigue, and improve quality of life 
of FM patients [30]. Although pregabalin, duloxetine and milnacipran are FDA 
approved for the treatment of FM, currently prescribed drugs appear to have little 
effect on reducing healthcare utilization [31]. The effectiveness of current 
medications is limited and many patients discontinue use due to the incidence of 
adverse effects [32,33]. 
Advances in the understanding of the pathophysiology of FM has started to provide 
clues to the underlying mechanisms offering potential targets for new medications 
(Figure 1). Pharmacological treatment focused to the modulation of the central 
neurotransmitters, serotonin, noradrenaline, dopamine, glutamate and substance P 
would be compatible with the central component in the pathophysiology of FM [8,30]. 
Interestingly, greater efficacy has been observed with drugs that inhibit the re-uptake 
of both serotonin and noradrenaline, modulating at least the DNIC descending 
inhibitory pathways, relative to selective inhibition of each neurotransmitter [30]. In 
addition, the α2δ ligand pregabalin probably achieves benefit by targeting glutamate 
and substance P disturbances. The inconsistent success for FM patients of current 
treatments has led to investigation of bioamine modulation and α2δ ligands in 
addition to novel targets such as dopamine receptors, NMDA receptors, cannabinoid 
receptors, angiotensin receptors, melatonin receptors and potassium channels for 
the development of potential drug therapies. Table 1 lists potential drug therapies 
with specified mechanisms of action exhibiting potential efficacy for the treatment of 
FM.  
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3. Search strategy 
New and emerging drugs being actively developed in FM clinical trials were reviewed 
following a comprehensive search of Pubmed, Google, Google Scholar, 
ClinicalTrials.gov, adisinsight.springer.com and Controlled-trials.com without date 
restrictions up to 31 January 2016. ClinicalTrials.gov was initially searched using 
broad terms for fibromyalgia, medications and treatments. The results of this search 
provided the terms, names of drugs, sponsors, and mechanisms of action that were 
used in a systematic search the other databases. Studies identified for drugs already 
marketed for FM were excluded. Google enabled the identification of sources not 
formally published, such as company and academic institution websites, scientific 
meeting abstracts. Potential agents that formed the subject of studies whether non-
successful or discontinued were considered to provide an understanding of the 
therapeutic targets investigated. 
 
4 Potential therapies 
4.1 Bioamine neurotransmitters 
Abnormalities in bioaminergic neurotransmitters (noradrenaline, serotonin and 
dopamine) have been associated with the core clinical symptoms of FM and 
modulators of these systems have gained interest are potential treatments [8]. 
Cyclobenzaprine (flexeril, Amrix) is a tricyclic antidepressant with muscle relaxant 
properties that exhibits noradrenaline and serotonin reuptake inhibition. A meta-
analysis of randomized controlled trials conducted in the 1990s demonstrated that 
cyclobenzaprine, after 4 to 24 weeks, treatment evoked overall improvement in FM 
patients with moderate reductions in the individual symptoms of pain and sleep 
dysfunction [34]. A recent double-blind randomized placebo-controlled trial has 
provided further evidence in FM patients that very low-dose cyclobenzaprine (1-4mg 
at bedtime) improved sleep, decreased fatigue, pain and tenderness and improved 
mood after 8 weeks [35]. In a 12-week, randomized, double-blind, placebo-controlled 
trial TNX-102 SL (Tonmya) sublingual very low dose (VLD) cyclobenzaprine (2.8mg 
at bedtime) evoked a significant improvement on sleep quality associated with 
improvements in multiple other symptoms, such as pain in patients with FM 
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compared to placebo [36]. Significant improvements with Tonmya were also 
observed on several fibromyalgia impact questionnaire (FIQ) items (pain, sleep 
quality, anxiety, stiffness, and sensitivity). 
TD-9855 is a noradrenaline and serotonin reuptake inhibitor developed to treat 
chronic pain and ADHD [37]. In a double-blind placebo-controlled 6-week study TD-
9855 (20mg) significantly reduced pain, fatigue and the FIQ score and improved 
quality of life [37]. 
Selective serotonin enhancement has been studied with paroxetine (12.5-62.5 
mg/day), a selective serotonin reuptake inhibitor, in patients with FM. Pain, 
depression and anxiety, sleep improvement and functionality increase was assessed 
in FM patients and paroxetine improved the overall symptomatology [38]. However, 
paroxetine failed to significantly reduce the pain associated with FM. Trazodone is a 
second-generation antidepressant of the serotonin antagonist and reuptake inhibitor 
(SARI) class with strong sedative activity. In a 12-week open-label study trazodone 
(50-300mg/day) markedly improved sleep quality, sleep duration and sleep efficiency 
with more moderate effects on FIQ scores, anxiety, depression and pain [39]. In a 
second open-label study, patients who experienced benefit to trazodone (50-300 
mg/day) after 12-weeks treatment received pregabalin (75-450 mg/day), added to 
the trazodone treatment for an additional 12-week period [40]. Again trazodone 
significantly improved global fibromyalgia severity, sleep quality, and depression, as 
well as pain interference with daily activities. After pregabalin combination additional 
and significant improvements were seen on fibromyalgia severity, depression and 
pain interference with daily activities, and a decrease in bodily pain was also 
apparent [34]. 5-hydroxytryptamine (5-HT) 3 receptors are located on neurons in the 
central and peripheral nervous system, and activation has been shown to cause 
release of neuropeptides, such as substance P, involved in pain processing [41,42]. 
Thus, the stimulation of 5-HT3 receptors may be responsible for widespread pain 
mediated by substance P. The 5-HT3 receptor antagonist, dolasetron, (12.5mg/d iv 
intermittent) in a randomised, double-blind, placebo-controlled trial of patients with 
FM reduced pain greater than observed in the placebo group [43]. The secondary 
outcomes (e.g. fatigue, quality of life) failed to achieve a significant change. Thus, 
dolasetron was limited to controlling only pain in FM and required to be administered 
intravenously. Mirtazapine is a selective antagonist at 5-HT2 and 5-HT3 receptors 
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which also blocks α2 adrenergic auto-receptors in the CNS. In a randomized 
placebo-controlled pilot study, mirtazapine (30mg per day) exhibited significant within 
group improvement of pain and FIQ [44]. Thus in contrast, to combined modulation 
of serotonin and noradrenaline levels, treatments selective for the serotonergic 
system produced inconsistent outcomes in FM patients. 
Enhancement of the noradrenaline response only has also been studied as a 
treatment approach to FM. The selective noradrenaline reuptake inhibitor 
esreboxetine (4, 8 or 10 mg/day), the active enantiomer of reboxetine, has been 
studied in a double-blind, randomized, placebo-controlled study [45]. Although 
esreboxitine improved pain, fatigue, FIQ and quality of life scores in patients with FM, 
the efficacy lacked a dose-response relationship. Droxidopa, a prodrug of 
noradrenaline, increases CNS levels of noradrenaline [46]. In a double-blind 
placebo-controlled proof-of-concept study droxidopa monotherapy (200, 400 or 
600mg three times daily) or in combination with carbidopa (25 or 50mg three times a 
daily) reduced pain and FIQ scores in patients with FM, however significance 
compared with placebo treatment was not observed [47]. The enhancement of 
noradrenaline levels alone does suggest utility in FM, however current evidence from 
drugs studied is not consistent as a treatment approach.  
 
Patients with FM have been reported to have an abnormal dopamine response and 
dopamine D2/D3 receptor availability to pain [48,49]. Consequently, dopamine 
D3/D2 receptor agonists have been tested in patients with FM in an attempt to rectify 
this dysfunction. Pramipexole (4.5mg once daily) demonstrated therapeutic benefit in 
a double-blind, placebo-controlled FM trial with improvements in pain, fatigue and 
overall function determined by a reduction in the FIQ total score [50]. Pain was 
decreased by 50% or greater in 42% of patients (but only 14% receiving placebo), 
with the most common adverse effects, anxiety and weight loss, were transient. 
Concomitant medications were being taken by most patients in this trial, but it was 
not clarified whether the improvements due to pramipexole were a summative effect 
or those FM symptoms not contained by current therapies. The benefits of 
modulation of the dopaminergic system by dopamine agonists however is not clear 
because the dopamine agonists ropinirole and terguride failed to evoke a significant 
therapeutic response in patients with FM [51,52]. 
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The inconsistency of clinical data for drugs that individually target the serotonin, 
noradrenaline or dopamine pathways in patients with FM again supports the 
requirement of therapies that modulate more than one of the dysfunctional 
neurotransmitters, as observed with SNRIs and tricyclic antidepressants. A multi-
target approach was further supported with the serotonin/noradrenaline/dopamine 
reuptake inhibitor, sibutramine, which improved the pain, sleep and fatigue in 
patients with FM; the symptoms returned within 3-7 days when treatment was 
terminated [53]. 
Focus on drugs that target the activities of both dopamine and noradrenaline have 
received attention as a treatment approach to FM. Modafinil and armodafinil are non-
amphetamine stimulants that release dopamine and noradrenaline in the CNS and 
histamine in the hypothalamus. In the regions of the brain where fatigue is believed 
to be interpreted modifinil and armodafinil are proposed to elevate histamine, 
noradrenaline, serotonin, glutamine and dopamine activity [54], thus treatment may 
allow the brain to interpret a lower fatigue state in patients with FM. In retrospective 
studies, fatigue associated with FM was reported to be reduced by modafinil [55]. 
However, armodafinil (50-250mg/d), in a proof-of-concept blinded, randomized 
placebo-controlled study, however failed to treat the fatigue associated with FM; 
however, a large placebo effect (up to 46%) was observed in the patient population 
making interpretation of the outcomes unreliable [55]. Methylphenidate (Ritalin; 10-
60mg/day), a neuronal stimulate that inhibits dopamine and noradrenaline reuptake, 
has been observed to enhance mood and concentration in patients with FM after 30-
day treatment, although other symptoms such as pain intensity failed to improve [56].  
Due to the limited efficacy observed with antidepressants modulating bioamines and 
the α2δ ligands, pregabalin and gabapentin, in the management of FM symptoms the 
potential of greater benefit or more preferable outcomes from combined 
pharmacological therapies has been considered. In a single-blind randomized trial, 
the combined use of pregabalin (75 mg/day) plus paroxetine (25 mg/day), 
amitriptyline (25 mg/day) or venlafaxine (75 mg/day) resulted in significantly lower 
somatic symptom and depression scale scores, better life satisfaction, mood, and 
sleep quality, higher medication tolerability, and less frequent adverse effects in 
patients with FM [57]. 
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 4.2 Antipsychotic drugs 
Second generation antipsychotic drugs have attracted interest in the treatment of 
chronic pain which is consistent with the receptor affinities exhibited [58]. This has 
led to the testing of antipsychotic drugs in FM. In a pilot double-blind, randomized, 
placebo-controlled study the antipsychotic drug quetiapine (up to 300 mg daily), that 
has affinity for D2, 5-HT2A, H1, alpha1 and 5-HT1A receptors demonstrated 
significant benefits on sleep but not against the other symptoms of FM [59]. However, 
in patients with a dual diagnosis of major depressive disorder and FM quetiapine (50 
to 300 mg daily) significantly improved depression, pain and quality of life scores [60-
62] No significant differences were found between quetiapine XR and amitriptyline 
treatments for any of the secondary outcomes measured in patients with major 
depressive disorder and FM [61]. Use of quetiapine in fibromyalgia should therefore 
be limited to patients with comorbid major depression or have unresolved and 
disabling depressive and/or anxiety symptoms.  
The antipsychotic amisulpride has preferential affinity for pre-synaptic dopamine D2 
and D3 autoreceptor subtypes but also acts as a potent antagonist at the 5-HT7 
receptor [63]. In contrast to quetiapine, amisulpride in an open-label study did not 
provide any benefits as a treatment of FM [64]. Interestingly, ziprasidone which has 
affinity for the dopamine D2 and D3, the serotonin 5-HT2A, 5-HT2C, 5-HT1A, 5-
HT1D, α1-adrenergic receptors and histamine H1 receptor and inhibits serotonin and 
noradrenaline reuptake of synaptic reuptake exhibits similarities to the pharmacology 
of quetiapine [63]. Ziprasidone also failed to provide an appropriate improvement in 
symptoms of patients with FM [65]. 
 
4.3 Anticonvulsants 
Mirogabalin (DS 5565), like pregabalin and gabapentin which have demonstrated 
efficacy in the treatment of FM, is an α2δ ligand [66]. Identification of α2δ-1 and α2δ-
2 subunits have shown that a ligand binding to the former contributes to analgesic 
effects, whereas binding to α2δ-2 appears to contribute to CNS side effects [67].  
Mirogabalin is a novel, preferentially selective α2δ-1 ligand with a unique binding 
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profile that may translate to clinically meaningful differences in both efficacy and 
safety [60].  In a double-blind, randomized, placebo-controlled study of diabetic 
peripheral neuropathic pain mirogabalin (5-30mg/day) reduced pain [66], results from 
a randomized, double-blind, placebo-controlled study of microgabalin for treatment of 
FM are awaited [68]. 
 
The efficacy of anticonvulsants is based on the ability to suppress neuronal hyper-
excitability, thus drugs exhibiting mechanism of action other than α2δ ligand have 
gained interest as treatments of FM. Levetiracetram binds to a synaptic vesicle 
glycoprotein, SV2A, and inhibits presynaptic calcium channels reducing 
neurotransmitter release [69]. Several cellular targets have been proposed to be 
relevant to the therapeutic activity of topiramate involves several cellular targets 
which includes inhibition of voltage-activated calcium channels, although the 
relevance to clinical activity is uncertain [70]. The mechanism of action of lacosamide 
is not fully defined but is believed to act through voltage-gated sodium channels [71]. 
Although pregabalin and gabapentin, have exhibited beneficial effects in the 
treatment of FM reducing pain, fatigue and sleep disturbance [66], evidence was 
insufficient to draw conclusions on the efficacy of levetriactem, topiramate and 
lacosamide in the treatment of FM [72,73].  
 
4.3 Glutamate 
Memantine is an NMDA glutamate receptor antagonist that has been studied in a 
double-blind, randomized placebo-controlled trial to assess pain threshold, pain 
perception, cognitive state, anxiety and depression in FM patients [74,75]. 
Preliminary evidence of memantine as a treatment of FM demonstrated a significant 
decrease in pain with an improvement in all other secondary outcomes except 
anxiety. Memantine treatment resulted in an increase in cerebral metabolism in FM 
patients with a correlation between choline levels and the FIQ score in the posterior 
insula [76].  
Yokukansan (TJ-54), a traditional Japanese medicine, is used in clinical situations 
for treating psychiatric disorders by acting mainly on the glutamatergic and 
serotonergic nervous system [77]. Yokukansan has demonstrated clinical efficacy in 
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neuropathic pain conditions with suggested greater effectiveness than traditional 
medicines, such as tricyclic antidepressants, carbamazepine, gabapentin, and 
opioids [78]. Although the mechanism of Yokukansan on neuropathic pain has not 
been established, the potential of alleviating pain in FM have been suggested and 
the outcomes of clinical trials are awaited [79,80]. 
 
4.4 Substance P  
Patients with FM have raised levels of substance P within the CNS which could lead 
to the induction of pain through the activation of neurokinin1 (NK1) receptors [9]. 
Thus, NK1 receptor antagonists could provide a novel therapeutic approach to 
counteract central pain transmission. Casopitant, an NK1 receptor antagonist, has 
been evaluated in a double-blind randomized, placebo controlled trial in FM patients 
with comorbid depression, and outcomes are awaited [81]. Capsaicin desensitizes 
nociceptive processes possibly due to depletion of substance P, thus preventing 
sensory factors activating central neuronal mechanisms responsible for the 
symptoms of FM. Capsaicin binds to the transient receptor potential vanilloid 1 
subunits (TRPV1) which are located in peripheral nociceptors [82]. Topical capsaicin 
therapy (0.075% 3 times daily for 6 weeks) significantly improved myalgic scores, 
pain threshold and fatigue, in addition to mood variables in patients with FM that was 
unresponsive to other treatments [83]. Thus, suppression of the actions of substance 
P appear to offer benefit in the treatment of FM and further investigations are 
required.  
 
4.5 Naltrexone 
Although naltrexone is an opioid receptor antagonist used in the treatment of alcohol 
and opioid dependence, low-dose naltrexone (LDN) has exhibited benefit in the 
treatment of diseases not related to chemical dependency or intoxication. LND (4.5 
mg/day) in a double-blind, randomized, placebo-controlled study in FM patients 
reduced the pain and depressed mood, but not fatigue and sleep disorder [84]. 
Microglia antagonism has been suggested as the novel mechanism by which LDN 
reduces the FM severity [84]. Microglia, which may be abnormally sensitized in FM, 
can release pro-inflammatory factors in the CNS which interact with neurons, leading 
to the central facilitation of pain processing [85]. 
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 4.6 Cannabinoids 
FM has been proposed to be a form of endocannabinoid deficiency which has led to 
the evaluation of cannabinoids as a treatment approach [80]. Evidence in 
uncontrolled trials of efficacy of cannabinoids for FM symptoms, although 
inconsistent, has suggested benefits [87]. In double-blinded, placebo-controlled 
studies nabilone (0.5-1.0 mg before bedtime) after 4 weeks evoked a significant 
reduction in pain and anxiety and improvement in quality of life in FM patients [88, 
89]. The role of cannabinoids in the treatment of FM is being further investigated with 
dronabinol (a synthetic form of delta-9-tetrahydrocannabinol, THC) and ZYN001, a 
pro-drug of delta-9-tetrahydrocannabinol. Dronabinol (mean daily dose of 7.5mg) 
produced a significant reduction in pain intensity and depression in patients with FM 
leading to an improvement of quality of life in those patients able to tolerate 
(approximate 25% drop out rate) the treatment [90]. ZYN001 is the D-(-)-glyceric acid 
ester of THC which is rapidly hydrolysed by esterases in the skin to THC [91]. 
Transdermal delivery should provide stable plasma levels and avoid first-pass 
hepatic metabolism associated with THC metabolite psychotropic effects thereby 
improving the tolerability profile in FM patients [92].  
 
4.8 Potassium channel 
Flupirtine is a centrally acting, non-opiate analgesic that activates Kv/M-channel 
activity and indirectly suppresses NMDA receptor activity resulting in the inhibition of 
sustained neuronal activity associated with pain [93]. Effective analgesia has been 
observed in acute pain conditions, such as traumatic injury, headache and migraine, 
and in chronic musculoskeletal pain [94]. Initial evidence supports the use of 
flupirtine as a treatment approach in FM patients where a reduction of pain, sleep 
disturbance, fatigue and depressive symptoms was observed [95]. Controlled clinical 
studies are required for the confirmation of the utility of flupirtine in FM. 
 
4.9 Melatonin 
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Melatonin, N-acetyl-5-methoxy tryptamine, is involved in the regulation of sleep. In 
addition to sleep-inducing properties melatonin and novel melatonin analogues, such 
as ramelteon, have exhibited analgesic properties suggesting potential use in the 
management of pain and insomnia of chronic pain conditions such as FM [96]. In an 
open 4-week pilot study melatonin (3 mg at bedtime) significantly improved severity 
of pain, tender point count and sleep quality, but not fatigue, depression and anxiety 
in patients with FM [97]. Improvement of the FM symptoms of pain, sleep disorder 
and depression were further demonstrated in double-blinded randomized trials with 
melatonin alone and in combination with fluoxetine or amitriptyline [98,99]. Hussain 
et al [98] observed that melatonin (3 or 5 mg per day) reduced the pain, sleep 
disorder, depression and anxiety in patients with FM in contrast to fluoxetine (20 mg 
per day) which only decreased anxiety, depression and fatigue. The combination of 
melatonin and fluoxetine was effective in the treatment of most of the symptoms of 
FM. In a 6 week randomized controlled trial, melatonin (10 mg per day), amitriptyline 
(25 mg per day) and melatonin (10 mg per day) plus amitriptyline (25 mg per day) 
significantly improved the pain and sleep quality in patients with FM [99]. Compared 
with amitriptyline alone, melatonin alone or in combination with amitriptyline gave 
superior improvement in symptoms, with the combination producing only marginal 
additional clinical effects. The melatonin analogue agomelatine exhibits both high-
affinity human melatoninergic MT1 and MT2 receptors agonist and a serotonin 5-
HT2C receptor antagonist properties. In two 12 week open-label studies agomelatine 
(25-50 mg per day) also significantly improved pain, depression and anxiety 
symptoms in patients with FM [100,101]. But in contrast to melatonin, an 
improvement in sleep quality was not seen with agomelatine [101]. The stimulation of 
melatoninergic receptors is associated with effectiveness in analgesia and mood 
treatment of patients with FM, but control of the sleep disorder is inconsistent.  
 
4.10 IMC-1 
IMC-1 is a fixed-dose-combination of the anti-herpes virus nucleoside analog 
famciclovir and celecoxib developed as a treatment for FM, irritable bowel syndrome, 
chronic fatigue syndrome/ME, and other conditions that may share a similar 
underlying pathophysiology [102,103]. In a double-blinded, randomized, placebo-
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controlled Phase II study IMC-1, evoked significant reductions in pain, fatigue and 
FIQ scores with improvements in functionality and quality of life at 16 weeks in 
patients with FM [103]. The outcomes of the study with IMC-1 suggest that tissue-
resident herpes virus may be causally related to FM symptoms or recurrence. 
 
 
5. Conclusion  
The effectiveness of current medications for FM is limited and many patients 
discontinue use due to the incidence of adverse effects. Consequently, the number 
of drugs being investigated emphasizes the continued interest and need to improve 
the management of FM. The majority of drugs under investigation are focused 
towards controlling the hyper-excitability of the central neuronal system. Although 
benefits have been demonstrated involving a diversity of pharmacological targets, 
the complexity of FM has resulted in limitations and barriers in drug development. Of 
the drugs investigated none have provided substantial improvement across the 
spectrum of symptoms of FM leading to clues of the preferential pharmacology 
targets for the optimal treatment of the condition. 
 
6 Expert opinion 
Treatment of FM has been identified as requiring both pharmacological and non-
pharmacological approaches often with an empiric approach to drug therapy focused 
toward individual symptoms with an emphasis to pain. The pharmacological 
approach of current and potential therapies has been primarily directed towards 
suppression of the central hyper-excitability associated with the pathophysiology of 
FM. This has resulted in the evaluation of a range of molecular targets and 
mechanisms such as bioamine modulation, α2δ ligands, dopamine receptors, NMDA 
receptors, cannabinoid receptors, melatonin receptors and potassium channels that 
have the potential of suppressing neuronal activity. Although some of the drug 
treatments discussed are capable of improving health status in patients with FM, not 
all symptoms were resolved by a single drug and often the consistency of efficacy 
associated to an individual mechanism of action was not always observed. The 
range of efficacies, from partial to none, demonstrated by the various therapeutic 
D
ow
nl
oa
de
d 
by
 [S
he
ffi
eld
 H
all
am
 U
niv
ers
ity
], 
[K
im
 L
aw
so
n]
 at
 04
:48
 08
 Ju
ne
 20
16
 
approaches in recent clinical trials have provided, albeit limited, insight into potential 
drug treatment profiles and important clues for condition-focused therapies and 
improved diagnosis. But barriers in drug development continue to be encountered for 
the identification of new and improved therapies for FM. The existence of subgroups 
of FM has been proposed by many studies [104]. The heterogeneity of the condition 
may be responsible for the modest and limited efficacy often observed. Most of the 
clinical trials and studies of the pathophysiology of FM and treatments have not 
taken into account subgrouping and have been directed by the comparison of 
average outcomes of patient populations. In addition, consideration of targeting 
peripheral mechanisms that contribute to the pathophysiology and possible act as 
sensory input generators has received limited and inconsistent attention. Although 
drug monotherapy would be the optimum treatment approach, the multidimensional 
aspects of FM and its high comorbidity with other disorders is consistent with the 
requirement of combination therapy using drugs targeting different molecular 
mechanisms and thereby symptoms.  
Although a significant proportion of pain patients adequately respond to current 
analgesics, many patients, such as those with FM do not achieve an adequate 
experience and often present with major adverse effects. A greater understanding of 
the pathophysiology of FM, particularly the role of aberrant CNS functioning leading 
to heightened generalized sensitization to sensory input and peripheral input 
generators, and efficacy clues gained from current drug investigations has directed 
interest to a range of potential targets for the identification of new medications. 
Several existing drugs have demonstrated efficacy in chronic pain conditions and 
these novel analgesics could offer potential in the treatment of the symptoms of FM 
[105]. Repurposing of drugs, identifying new uses for existing drugs, bypasses most 
of the time and cost consuming components of drug development. Thus, these 
approaches could not only expand the options for the identification of the direction 
required for condition-focused drugs, but also readily make products available in the 
usual-care setting. Although the primary endpoints of recent clinical trials with FM 
patients have changed with more recent attention to global health status rather than 
over emphasis on any single particular symptom, the ability to transfer the observed 
outcomes to management requires confirmation.  
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 Figure 1. Pathophysiological processes associated with fibromyalgia that have been 
identified as potential drug targets. Core symptoms of the condition are indicated in 
boxes. HPA – hypothalamic pituitary adrenal axis; SNS – sympathetic nervous 
system. 
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106. Table 1. Emerging drug therapies with potential efficacy for the treatment of fibromyalgia.  
Drug Mechanism of Action Domains 
accessed 
Trial Sponsor Status 
AGN203818 α2 adrenergic agonist pain Allergan Terminated 2015, 
outcome not published 
Agomelatine Melatoninergic 
receptor agonist and 
5-HT2 receptor 
antagonist 
pain,  
mood, 
cognitive 
function 
University of 
Messina 
Phase II, improved pain 
and mood 
Capsaicin transient receptor 
potential vanilloid 1 
subunits (TRPV1) 
myalgic, pain, 
fatigue scores 
Rheumatology 
Service at the 
Specialist Clinic of 
Cantabria 
Phase II, improved 
symptoms 
Casopitant 
(GW679769) 
Neurokinin1 receptor 
agonist 
FIQ GlaxoSmithKline Phase II completed 
Dolasetron 5-HT3 receptor 
antgonist 
pain, fatigue, 
quality of life 
University Hospital 
of Limoges, France 
Phase II, reduced pain 
only 
Dronabinol Cannabinol pain, 
depression, 
quality of life 
Heidelberg 
University 
Phase II, reduced pain 
and depression 
Droxidopa Noradrenaline prodrug pain, FIQ Chelsea 
Therapeutics 
Phase II, improved 
symptoms 
DS-5565 α2δ ligand pain Daiichi Sankyo Phase II planned 
EMA401 Angiotensin II receptor 
antagonist 
pain Spiniflex Phase II planned 
Esreboxetine Noradrenaline 
reuptake inhibitor 
pain, FIQ, 
fatigue, quality 
of life 
Pfizer Phase II, improved 
symptoms 
Flupirtine Potassium channel 
activation 
pain, FIQ Lupin Phase II planned 
IMC-1 Viral suppression of 
herpes virus 
pain, fatigue, 
FIQ 
Innovative Med 
Concepts 
Phase II, improved 
symptoms 
Levetiracetam Synaptic vesicle 
glycoprotein ligand 
pain UCB Pharma & Uni 
of California 
Phase II, inconclusive 
outcomes 
Memantine NMDA antagonist pain,  
cognitive state, 
depression 
Aragon Institute of 
Health Sciences 
Phase II, improved 
symptoms 
Mirtazapine 
(Org 3770)  
Adrenergic and 
serotonin receptor 
antagonist 
pain, FIQ Meiji Seika Pharma 
Co., Ltd. 
Pilot, reduced pain and 
FIQ scores 
Nabilone Cannabinoid receptor 
agonist 
pain, sleep, 
quality of life 
Winnipeg Regional 
Health Authority 
Phase II, improved 
symptoms 
Naltrexone Opioid receptor 
antagonist 
pain, fatigue, 
mood, sleep 
Stanford University Phase II, improved pain 
and mood 
Neurotropin Neuromodulator pain Yukioka Hospital, 
Osaka 
Phase II, reduced pain 
Paroxetine Serotonin reuptake 
inhibitor 
pain, mood, 
sleep, 
functionality  
Duke University 
Medical Center, 
USA & 
GlaxoSmithKline 
Phase II, improved 
symptoms 
Pramipexole Dopamine agonist FIQ Boehringer 
Ingelheim 
Phase II, improved 
symptoms 
Quetiapine Antipsychotic FIQ East Tennessee 
State Uni &  
Astra Zeneca 
Phase II benefits limited 
to patient subgroup 
TD-9855 Noradrenaline 
serotonin reuptake 
inhibitor 
pain, fatigue, 
FIQ 
Theravance 
Biopharm 
Phase II, improved 
symptoms 
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TNX102SL 
cyclobenzaprine 
Noradrenaline, 
serotonin reuptake 
inhibition 
pain, sleep  Tonix 
Pharmaceuticals 
Phase II improved 
symptoms. 
Trazodone 5-HT receptor 
antagonist and 
serotonin reuptake 
inhibitor 
FIQ Universidad de 
Granada  
EP Calandre 
Phase II, improved 
symptoms 
Yokukansan Herbal medication insomnia St. Marianna 
University School of 
Medicine 
Phase II planned 
ZYN001 Cannabinoid pain,  
quality of life 
Zynerba Phase II planned 
107.  
108. Sources of information, Medline(Pubmed), ClinicalTrials.gov, adisinsight.springer.com and 
Controlled-trials.com. 
109. FIQ – fibromyalgia impact questionnaire;  
110.  
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